insights_auto
Outlook: 75.0% bullish·0.0% bearish
Go to analysischevron_right
PGEN:NASDAQ
Precigen Inc
$7.75
arrow_upward
+0.65%(+0.050) 1D
Sep 25, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PGEN...
Open
$8.08
High
$8.27
Low
$7.63
Mkt. cap
2.77B
Avg. vol.
4.84M
Volume
0.00
52-wk high
$8.27
52-wk low
$2.99
EPS
-$1.10
Beta
1.02
Shares outstanding
358.04M
No. of employees
160
Open
$8.08
High
$8.27
Low
$7.63
Mkt. cap
2.77B
Avg. vol.
4.84M
Volume
0.00
52-wk high
$8.27
52-wk low
$2.99
EPS
-$1.10
Beta
1.02
Shares outstanding
358.04M
No. of employees
160
News stories
From web sources and news partners
Simply Wall Street
·
1 day ago
Precigen (PGEN) Gains FDA Platform Backing As Its Valuation Story Gets Harder To Ignore
Stocktwits
·
2 days ago
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?
Investing.com
·
2 days ago
Precigen stock hits 52-week high at 8.05 USD
TipRanks
·
2 days ago
Precigen Stock Slips As Wall Street Turns Bullish
Profile
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. Wikipedia
About Precigen Inc
CEOHelen Sabzevari
Employees160
FoundedMay 21, 1998
Headquarters-
SectorBiotechnology
Websiteprecigen.com